{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Participants with Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Participants with Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Participants with Stable Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"ORR: The proportion of patients with complete response (CR) and partial response (PR). Follow-up assessments after cycle 16 to be done every 12 weeks for up to 24 months. Restaging imaging computed tomography (CT) scans to be repeated 12 and 24 months from the beginning of the follow-up period. Objective disease response (CR and PR) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL). CR = Disappearance of all evidence of disease; PR = Regression of measurable disease and no new sites.","groups":[{"description":"Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.","id":"OG000","title":"Brentuximab Vedotin Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"Up to 24 months post treatment","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}